These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Ebola Virus: Pathogenesis and Countermeasure Development. Furuyama W; Marzi A Annu Rev Virol; 2019 Sep; 6(1):435-458. PubMed ID: 31567063 [TBL] [Abstract][Full Text] [Related]
16. Review of Ebola virus disease in children - how far have we come? Dixit D; Masumbuko Claude K; Kjaldgaard L; Hawkes MT Paediatr Int Child Health; 2021 Feb; 41(1):12-27. PubMed ID: 32894024 [TBL] [Abstract][Full Text] [Related]
17. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. Tshiani Mbaya O; Mukumbayi P; Mulangu S Front Immunol; 2021; 12():721328. PubMed ID: 34526994 [TBL] [Abstract][Full Text] [Related]
18. Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics. Warren T; Zumbrun E; Weidner JM; Gomba L; Rossi F; Bannister R; Tarrant J; Reed M; Lee E; Raymond JL; Wells J; Shamblin J; Wetzel K; Donnelly G; Van Tongeren S; Lackemeyer N; Steffens J; Kimmel A; Garvey C; Bloomfield H; Blair C; Singh B; Bavari S; Cihlar T; Porter D Viruses; 2020 Jan; 12(1):. PubMed ID: 31941095 [TBL] [Abstract][Full Text] [Related]
19. Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors. Liu J; Trefry JC; Babka AM; Schellhase CW; Coffin KM; Williams JA; Raymond JLW; Facemire PR; Chance TB; Davis NM; Scruggs JL; Rossi FD; Haddow AD; Zelko JM; Bixler SL; Crozier I; Iversen PL; Pitt ML; Kuhn JH; Palacios G; Zeng X Sci Transl Med; 2022 Feb; 14(631):eabi5229. PubMed ID: 35138912 [TBL] [Abstract][Full Text] [Related]
20. A review on the antagonist Ebola: A prophylactic approach. Khan FN; Qazi S; Tanveer K; Raza K Biomed Pharmacother; 2017 Dec; 96():1513-1526. PubMed ID: 29208326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]